

November 19, 2020

The BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400 001

The National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 541540

Scrip Code: SOLARA

Dear Sirs,

Sub: Disclosure of Related Party Transactions pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to above, please find enclosed the disclosure of Related Party Transactions, on consolidated basis, for the half year ended September 30, 2020 drawn in accordance with applicable accounting standards.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Solara Active Pharma Sciences Limited



S. Murali Krishna
Company Secretary

**Disclosure of Related party transactions on a Consolidated basis for the half year ended 30th September 2020
(In pursuance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)**

**Solara Active Pharma Sciences Limited
Name of Related parties and Description of relationships**

KMP / Person holding significant interest in the company :

Bharat R Sessa	Chief Executive Officer (Appointed wef. Feb 6, 2020) Managing Director & Chief Executive Officer (Appointed wef. August 03,2020)
Jitesh Devendra	Managing Director (Resigned wef. August 03, 2020)
S Hariharan	Executive Director - Finance (Resigned as Chief Financial Officer wef. October 30, 2020)
Subhash Anand	Chief Financial Officer (Appointed wef. October 30, 2020)
R. Ramakrishnan	Independent Director
Nirmal P Bhogilal	Independent Director
Kausalya Santhanam	Independent Director
Deepak C Vaidya	Non-Executive Director
Ronald Tjeerd De Vries	Independent Director
Ankur Nand Thadani	Non-Executive Director (Appointed wef. May 16, 2019)
Arun Kumar	Person holding significant interest in the company
Rajesh Salwan	Chief Operating Officer (Appointed wef. October 30, 2020)
B Sreenivasa Reddy	Chief Operating Officer (Resigned wef. October 30, 2020)
S Murali Krishna	Company Secretary

Enterprises controlled, owned or significantly influenced by KMP or person holding significant interest in the company:

Strides Pharma Science Limited, India
 Devendra Estates LLP, India
 Devicam LLP, India
 Sequent Scientific Limited, India
 Alivira Animal Health Limited, India
 Tenshi Life Sciences Private Limited, India
 Aureo Life Sciences Private Limited, India
 Tenshi Kaizen Private Limited, India (formerly Higher Pharmatech Private Limited)
 Olene Life Sciences Private Limited, India
 GMS Tenshi Holdings Pte Limited, India
 Stelis Biopharma Private Limited, India
 Steriscience Private Limited, India (formely Sovizen Life Sciences Private Limited)
 Tenshi Active Pharma Sciences Limited, India
 Tenshi Life Care Private Limited, India
 Triphase Pharmaceuticals Private Limited, India
 Oncobiologics Inc., USA
 Naari Pharma Private Limited, India
 Hydra Active Pharma Sciences Private Limited, India
 Sequent Research Limited, India
 Chayadeep Properties Private Limited, India
 Tenshi Kaizen Inc., USA
 Tenshi Kaizen USA Inc., USA
 Batliboi Impex Limited, India
 Tenshi Life Sciences PTE Ltd, Singapore
 Biolexis Pte Ltd, Singapore
 Navad Life Sciences Pte Ltd, Singapore
 Aureo Pharmaceuticals Private Limited, India
 Tenshi Kaizen Pharma Pte Ltd, Singapore
 Tenshi Kaizen Private Limited, UK

Consolidated Related party transactions for the half year ended 30th September 2020

Rs. in Crores

Description	Related party	September 30, 2020
Sale of goods	Strides Pharma Science Limited	110.18
	Aurore Life Sciences Private Limited	0.05
	Alivira Animal Health Limited	11.44
Interest income	Tenshi Life Sciences Private Limited	1.23
Other operating revenue	Strides Pharma Science Limited	1.30
Other Income	Tenshi Life Sciences Private Limited	0.21
Purchase of goods	Alivira Animal Health Limited	3.72
	Sequent Scientific Limited	0.00
	Aurore Life Sciences Private Limited	0.18
Purchase of services	Sequent Research Limited	2.25
	Tenshi Kaizen Private Limited	2.50
	Batliboi Impex Limited	0.12
Recovery of expenses from	Sequent Research Limited	0.52
	Strides Pharma Science Limited	8.05
Reimbursement of expenses to	Strides Pharma Science Limited	1.89
	Tenshi Life Sciences Private Limited	0.72
	Sequent Research Limited	0.23
Rental Income	Sequent Research Limited	0.42
Rent & Maintenance for leased property	Devendra estates LLP	0.15
	Strides Pharma Science Limited	0.77
Advance received back	Tenshi Kaizen Private Limited	10.50
Loan received back	Tenshi Life Sciences Private Limited	50.00
Sitting fees paid to directors	Deepak C Vaidya	0.04
	Kausalya Santhanam	0.04
	Nirmal P Bhogilal	0.04
	Ronald Tjeerd De Vries	0.04
	R. Ramakrishnan	0.04
Services received in the capacity other than as KMP (refer note (i) below)	Subhash Anand	0.11
	Rajesh Salwan	0.14
Short term employee benefits paid to (refer note (i) below)	Jitesh Devendra	0.79
	S Hariharan	0.66
	Bharat R Sesha	1.04
	B Sreenivasa Reddy	0.57
	S Murali Krishna	0.19

note (i): The compensation excludes gratuity & compensated absences which cannot be separately identified from the composite amount advised by the actuary.